90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2

Lancet HIV. 2018 Jul;5(7):e390-e399. doi: 10.1016/S2352-3018(18)30094-8.


Distinct from HIV-1 and often neglected in the global campaign to end the AIDS epidemic, HIV-2 presents unique and underappreciated challenges in diagnosis, clinical care, antiretroviral therapy (ART), and HIV programmatic management. Here, we review the epidemiology and natural history of HIV-2, diagnostics and algorithms for accurately diagnosing and differentiating HIV-2 from HIV-1, the unique features of HIV-2 ART and drug resistance, and the clinical care and management of patients infected with HIV-2 in both developed and resource-limited settings. Ultimately, further research is needed to address the gaps in our knowledge of HIV-2 infection, increased resources are needed to specifically target HIV-2 as part of the UNAIDS/WHO 90-90-90 campaign to end AIDS, and increased determination is needed to better advocate for inclusion of people living with HIV-2 in global HIV/AIDS initiatives.

Publication types

  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • Developing Countries
  • Epidemics / prevention & control*
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Infections / prevention & control
  • HIV Infections / virology
  • HIV-2 / isolation & purification*
  • Health Resources
  • Humans
  • Point-of-Care Systems
  • Viral Load


  • Anti-Retroviral Agents